cbdMD, Inc. has demonstrated revenue resilience despite a persistent downtrend since 2022, driven by its recognized brand and an exclusive Amazon Amify platform agreement. The company’s operating losses have contracted notably in 2025, reflecting disciplined cost management but continued negative net income and cash flows highlight ongoing profitability challenges. Regulatory complexities around CBD products continue to impose growth ceilings and risk factors, while strategic acquisitions like Gaia Botanicals signal measured expansion efforts. Capital structure moves including a Series B preferred issuance and launch of a sizable equity compensation plan underpin financial flexibility and management alignment as cbdMD navigates a competitive and evolving market.